Unknown

Dataset Information

0

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity.


ABSTRACT: In earlier studies, galectin-9 (Gal-9) was identified as a multifaceted player in both adaptive and innate immunity. Further, Gal-9 had direct cytotoxic and tumor-selective activity towards cancer cell lines of various origins. In the current study, we identified that treatment with Gal-9 triggered pronounced membrane alterations in cancer cells. Specifically, phosphatidyl serine (PS) was rapidly externalized, and the anti-phagocytic regulator, CD47, was downregulated within minutes. In line with this, treatment of mixed neutrophil/tumor cell cultures with Gal-9 triggered trogocytosis and augmented antibody-dependent cellular phagocytosis of cancer cells. Interestingly, this pro-trogocytic effect was also due to the Gal-9-mediated activation of neutrophils with upregulation of adhesion markers and mobilization of gelatinase, secretory, and specific granules. These activation events were accompanied by a decrease in cancer cell adhesion in mixed cultures of leukocytes and cancer cells. Further, prominent cytotoxicity was detected when leukocytes were mixed with pre-adhered cancer cells, which was abrogated when neutrophils were depleted. Taken together, Gal-9 treatment potently activated neutrophil-mediated anticancer immunity, resulting in the elimination of epithelial cancer cells.

SUBMITTER: Ustyanovska Avtenyuk N 

PROVIDER: S-EPMC8772786 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7826360 | biostudies-literature
| S-EPMC6436859 | biostudies-literature
| S-EPMC4319429 | biostudies-literature
| S-EPMC3397251 | biostudies-literature
| S-EPMC2647680 | biostudies-literature
| S-EPMC8917381 | biostudies-literature
| S-EPMC3912228 | biostudies-literature
| S-EPMC1895263 | biostudies-literature
| S-EPMC5010945 | biostudies-literature
| S-EPMC8910629 | biostudies-literature